<DOC>
	<DOCNO>NCT00827359</DOCNO>
	<brief_summary>The purpose study determine certain feature tumor specimen sample prior therapy predict likelihood respond everolimus .</brief_summary>
	<brief_title>Biomarker Trial Everolimus Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>- Participants undergo CT ultrasound guide biopsy accessible tumor lesion begin study medication . - Everolimus tablet take orally day . Participants undergo physical exam ask question general health specific question problem might . Photographs take tumor assess response treatment . This do CT MRI scan . Blood test perform every 4 week . In addition , blood research purpose do day 1 every cycle . A urine test do every 4 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must least one site disease opinion investigator safely accessible CT guide biopsy metastasectomy . Safely accessible metastatic disease define include lesion palpable overlie viscera least 2cm size . Given paucity subcutaneous lesion RCC , lesion felt safe biopsy also allow . These lesion include pleuralbased tumor , peripheral liver lesion , kidney lesion bone lesion exophytic soft tissue component . As palpable lesion , lesion least 2cm size overlie viscera . At least one measurable site disease , biopsy site , accord RECIST criterial previously irradiate . Th patient previous radiation marker lesion ( ) , must evidence progression since radiation Metastatic renal carcinoma histologic confirmation treat center either primary metastatic lesion . Nonclear cell histology allow 18 year age old Minimum four week since major surgery , completion radiation , completion prior systemic anticancer therapy ( adequately recover acute toxicity prior therapy ) ECOG Performance status 1 less Adequate bone marrow , liver renal function outline protocol Fasting serum cholesterol &lt; 300mg/dL OR &lt; 7.75 mmol/L AND fast triglyceride &lt; 2.5 x ULN Life expectancy great 6 month Prior treatment investigation drug within precede 4 week Chronic treatment systemic steroid another immunosuppressive agent Patients receive immunization attenuate live vaccine within one week study entry study period Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastasis . Treated brain metastasis allow . Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS : Gamma Knife , LINAC equivalent ) combination deem appropriate treating physician . Patients CNS metastasis treat neurosurgical resection perform within 3 month prio day 1 exclude . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin Patients severe and/or uncontrolled medical condition condition could affect participation study Uncontrolled diabetes mellitus define fast serum &gt; 1.5 x ULN A known history HIV seropositivity . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus Patients active , bleed diathesis systemic anticoagulation . Aspirin permit . Women pregnant breast feeding , women/men able conceive unwilling practice effective method birth control . Patients receive prior treatment mTOR inhibitor . Patients know hypersensitivity everolimus rapamycins excipients . History noncompliance medical regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>everolimus</keyword>
</DOC>